ISGCT 2025 Scientific Program
ISGCT 2025 Scientific Program Wednesday, September 10, 2025 09:00 -09:15 Welcome Address (Main Hall)09:15 -10:00 Keynote Lecture: Functional characterization and therapeutic targeting of gene regulatory elements (Main Hall)10:00 -10:20 Analysis of Genome Editing Alterations and Functional Outcomes in CRISPR-Engineered Cells (Main Hall)10:20 -10:40 Gene Therapy for Deafness: Updates in Models, the Clinic and Challenges Ahead (Main Hall)10:40 -11:00 Potentiating T-cell mediated Anti-Tumor Immunity through metabolic modulation and receptor engineering (Main Hall)11:30 -11:50 Genetically engineered 3D skeletal muscle tissue constructs for controlling metabolic disorder (Main Hall)11:50 -12:10 Modelling and Modulating Antitumor Immunity with RNA nanoparticles in 3D-Bioprinted Tumoroids (Main Hall)12:10 -12:30 Next-Generation CAR-T Cell Therapies for Multiple Myeloma: Advancing Innovation at Hadassah (Main Hall)12:30 -12:38 From personalized BBB-on-Chip to pre-clinical BBB-targeted gene therapy for MCT8-deficiency (Main Hall)12:38 -12:46 Leveraging Nanobubble-Mediated Ultrasound to Improve CAR-T Efficacy in Solid Tumor Treatment (Main Hall)12:46 -12:54 CRISPR/Cas9 Genome Editing Using Lipid Nanoparticles for Hepatocellular Carcinoma Therapy (Main Hall)12:54 -13:02 CAR T-Cells Are Dysfunctional In The CNS (Main Hall)13:02 -13:10 Chimeric Antigen Receptor T Cells Targeting the IgE B Cell Receptor Specifically Eliminate Human IgE Producing B cells (Main Hall)13:10 -13:18 Successful Phase 1/2a Trial for Treating Chronic Hard to Heal Diabetic Foot Ulcers (Main Hall)15:00 -15:20 Harnessing Tumor-Infiltrating Lymphocytes to Produce Engineered Polyclonal Antibody Therapies (Main Hall)15:20 -15:40 mRNA-based T-cell immunotherapy: from ex-vivo to in-vivo (Main Hall)15:40 -15:48 Highly Efficacious Allogeneic CAR-MAIT Cells Targeting Solid Tumors (Main Hall)15:48 -15:56 MIRNA193A INHIBITS HEAD AND NECK CANCER CELL GROTH: EVIDENCE FROM CELL AND XENOGRAFT MODELS (Main Hall)15:56 -16:04 Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells Migrate and Differentiate into Myelinating Oligodendrocytes in the CNS of Experimental Multiple Sclerosis (Main Hall)16:04 -16:12 Precise Correction of Patient-Derived HSPCs Enables T Cell Differentiation in a Personalized SCID Gene Editing Strategy (Main Hall)16:12 -16:32 Gene-corrected regulatory T cell therapy for IL2RA deficiency (Main Hall)16:32 -16:52 Synthetic biology platforms for biomedical applications (Main Hall)16:52 -17:00 Closing Remarks (Main Hall)
